{"id":"clofenamide","rwe":[{"pmid":"3790195","year":"1986","title":"The influence of diuretics on the excretion and metabolism of doping agents. III. Etilamfetamine.","finding":"","journal":"Arzneimittel-Forschung","studyType":"Clinical Study"}],"tags":[{"label":"clofenamide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"C03BA07","category":"atc"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"clofenamidum","offLabel":[],"synonyms":["clofenamide","clofenamidum","monochlorphenamide"],"timeline":[],"approvals":[],"brandName":"Clofenamidum","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"clofenamide","explanation":"Imagine your body's cells have a complex communication system. Clofenamidum is thought to help regulate this system by influencing the way cells talk to each other. This can potentially help treat various conditions, but more research is needed to confirm its effects.","oneSentence":"Clofenamidum is believed to work by modulating the activity of certain enzymes or receptors, although the specific details of its mechanism are not well understood.","technicalDetail":"The precise mechanism of action of Clofenamidum is unclear, but it is likely to involve the inhibition or activation of specific enzymes or receptors involved in cellular signaling pathways."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/693","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CLOFENAMIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:10:33.489587","biosimilars":[],"competitors":[{"drugName":"quinethazone","drugSlug":"quinethazone","fdaApproval":"1963-04-10","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"chlortalidone","drugSlug":"chlortalidone","fdaApproval":"1960-04-07","relationship":"same-class"},{"drugName":"metolazone","drugSlug":"metolazone","fdaApproval":"1973-11-27","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"indapamide","drugSlug":"indapamide","fdaApproval":"1983-07-06","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"clofenamide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"quinethazone","brandName":"quinethazone","genericName":"quinethazone","approvalYear":"1963","relationship":"same-class"},{"drugId":"chlortalidone","brandName":"chlortalidone","genericName":"chlortalidone","approvalYear":"1960","relationship":"same-class"},{"drugId":"metolazone","brandName":"metolazone","genericName":"metolazone","approvalYear":"1973","relationship":"same-class"},{"drugId":"indapamide","brandName":"indapamide","genericName":"indapamide","approvalYear":"1983","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"582ILN204B","CHEBI":"CHEBI:31418","INN_ID":"1396","UMLSCUI":"C2699364","ChEMBL_ID":"CHEMBL1865258","KEGG_DRUG":"D01822","DRUGBANK_ID":"DB13663","PUBCHEM_CID":"69594"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"C03BA07","allCodes":["C03BA07","C03BB07"]},"biosimilarFilings":[],"recentPublications":[{"date":"1986 Sep","pmid":"3790195","title":"The influence of diuretics on the excretion and metabolism of doping agents. III. Etilamfetamine.","journal":"Arzneimittel-Forschung"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clofenamidum, also known as CLOFENAMIDE, is a small molecule drug in the clofenamide class. Its original development is attributed to an unknown entity, and its current ownership is also unclear. The exact target of Clofenamidum is unknown, and it has not been approved by the FDA for any indications. As a result, there is limited information available on its commercial status, pharmacokinetics, or safety profile. Further research is necessary to determine the potential therapeutic applications and risks associated with Clofenamidum.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}